The effect of cholinesterase inhibitors on risk of nursing home placement among medicaid beneficiaries with dementia

Alzheimer Disease and Associated Disorders

Volumn 20, Issue 3, 2006, Pages 147-152

  Becker, Marion ^a   Andel, Ross ^b,c   Rohrer, Lodi ^a   Banks, Steven M ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer disease; Dementia; Institutionalization; Nursing home

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONFIDENCE INTERVAL; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; INSTITUTIONALIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; NURSING HOME; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSTITUTIONALIZATION; MALE; MEDICAID; MIDDLE AGED; NURSING HOMES; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT;

EID: 33747518304     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200607000-00005     Document Type: Article

References (38)

1. Gessert CE, Hyer K, Kane RL, et al. Cognitive impairment and quality of life: views of providers of long-term care services. Alzheimer Dis Assoc Disord. 2005;19:85-90.
2. Ferri CP, Prince M, Brayne C, et al. Global dementia prevalence: a Delphi Consensus Study. Lancet. 2005;366:2112-2117.
3. Henderson AS, Jorm AF. Definition and epidemiology of dementia: a review. In: Maj M, Sartorius N, eds. Dementia. Chichester, UK: John Wiley & Sons; 2003.
4. Hendrie HC. Epidemiology of dementia and Alzheimer disease. Am J Geriatr Psychiatry. 1998;6:S3-S18.
5. Kane RL, Ouslander JG, Abrass IB. Essentials of Clinical Geriatrics. 5th ed. New York: McGraw Hill; 2004.
6. Friedman SM, Steinwachs DM, Rathouz PJ, et al. Characteristics predicting nursing home admission in the program of all-Inclusive care for elderly people. Gerontologist. 2005;45:157-166.
7. MetLife. The MetLife Market Survey of Nursing Home and Home Care Costs. Westport, CT: MetLife Mature Market Institute; 2004.
8. Agency for Health Care Administration. Florida Medicaid Nursing Homes 1/1/2005 Rate Semester Initial Per Diems. Retrieved May 28, 2005. Available at http://ahca.myflorida.com/Medicaid/cost_reim/pdf/2005_01_initial_rates.pdf.
9. O'Brien EO. Long-term Care: Understanding Medicaid's Role for the Elderly and Disabled. The Kaiser Commission on Medicaid and the Uninsured. Washington, DC: The Kaiser Family Foundation; 2005.
10. Crayton G. A look at Florida's Medicaid Program. Presentation at the Medicaid Reform Symposium: The Future of Florida Medicaid. Orlando, FL, July 12, 2004.
11. Hareven TK. Historical perspectives on aging and family relations. In: Binstock RH, George LK, eds. Handbook of Aging and the Social Sciences. 5th ed. New York: Academic Press; 2001:141-159.
12. Samuels SC, Davis KL. Pharmacological treatment of dementia. In: Hof P, Mobbs C, eds. Functional Neurobiology of Aging. San Diego, CA: Academic Press; 2001:131-143.
13. Wilcock G, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter randomized controlled trial. BMJ. 2000;32:1-7.
14. Ritchie CW, Ames D, Clayton T, et al. Meta-analysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry. 2004;12:358-369.
15. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
16. Whitehouse PJ. The History of Therapeutic Trials in Dementia. Oxford: Taylor & Francis Medical Publishers; 2004.
17. Cummings JL. Use of cholinesterase inhibitors in clinical practice. Am J Geriatr Psychiatry. 2003;11:131-145.
18. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (Cochrane Review). In: The Cochrane Library. Issue 1. Art.No: CD005593. DOI:10 1002/14651858. Updated January 25, 2006.
19. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc. 2003;51:737-744.
20. Geldmacher D, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937-944.
21. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003;20:777-789.
22. Farlow MR, Hake A, Watson D, et al. Response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001;58:417-422.
23. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15 week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021-1031.
24. Gaugler JE, Edwards AB, Femia EE, et al. Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement. J Gerontol B Psychol Sci Soc Sci. 2000;55B:P247-P255.
25. Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:310-314.
26. Lopez OL, Becker JT, Saxton J, et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc. 2005;53:83-88.
27. Courtney C, Farrell D, Hills R, et al. Long-term donepezil treatment for 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet. 2004;363:2105-2115.
28. Albert SM, Sano M, Marder K, et al. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology. 1997;49:38-43.
29. Schneider LS, Olin JT, Lyness SA. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997;45:923-928.
30. Bravo G, Dubois M, Herbert R, et al. Evaluation of the Charlson comorbidity index for use in long-term care patients. J Am Geriatr Soc. 2002;50:740-745.
31. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Diseases. 1987;40:373-383.
32. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
33. Goldstein LB, Samsa GP, Matchar DB, et al. Charlson Index comorbidity adjustment for ischemic stroke outcomes. Stroke. 2004;35:1941-1945.
34. Allison PD. Survival Analysis the Using SAS System: A Practical Guide. Cary, NC: SAS Institute; 1995.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
36. Agüero-Torres H, von Strauss E, Viitanen M, et al. Institutionalization in the elderly: the role of chronic diseases and dementia. Cross-sectional and longitudinal data from a population-based study. J Clin Epidemiol. 2001;54:795-801.
37. Pandiani JA, Banks SM. Large data sets are powerful. Psychiatr Serv. 2003;54:745.
38. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.